Latest From CryoLife Inc.
Device fundraising during the fourth quarter totaled $2.6 billion, making it the strongest quarter of the year. Q4 M&A activity reached $3.9 billion, higher than Q3's $3.4 billion, but still one of the lowest quarters of the year. Both fourth quarter diagnostics financings and M&As hit an all-year low of $622 million, and $2.8 million, respectively.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2017.
The US Department of Justice is behind the Oct. 19 subpoena, which asks for more information and documents related to Merit’s marketing and promotional practices.
At $1.2 billion, Q4 device financing was the second-lowest quarter of 2015; M&A dollar volume was also low, but included multiple deals across various cardiovascular markets. Diagnostics financing was also down in Q4, totaling $403 million; acquisitions were worth $441 million.
- Implantable Devices
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- CryoLife Inc.
- Senior Management
Pat G Mackin, Chmn., Pres. & CEO
D. Ashley Lee, EVP, COO & CFO
David C Gale, PhD, VP, R&D
John Davis, SVP, Global Sales & Mktg.
- Contact Info
Phone: (770) 419-3355
1655 Roberts Blvd., NW
Kennesaw, GA 30144
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.